Phase 3Heart FailureRecruiting
IV Ferric Derisomaltose
Iron-Deficient Heart Failure
About this study
Phase 3 evaluation of intravenous ferric derisomaltose in patients with heart failure and iron deficiency to improve outcomes and quality of life.
Sponsor: Pharmacosmos
Key eligibility
- Adults with HFrEF or HFpEF
- Confirmed iron deficiency (TSAT <20% or ferritin criteria)
- Stable on guideline-directed therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.